Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening

References

• Alanazi, M. M., Elkady, H., Alsaif, N. A., Obaidullah, A. J., Alanazi, W. A., Al-Hossaini, A. M., Alharbi, M. A., Eissa, I. H., & Dahab, M. A. (2022). Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure, 1253, 132220. https://doi.org/10.1016/j.molstruc.2021.132220
   Web of Science ®Google Scholar
• Alanazi, M. M., Mahdy, H. A., Alsaif, N. A., Obaidullah, A. J., Alkahtani, H. M., Al-Mehizia, A. A., Alsubaie, S. M., Dahab, M. A., & Eissa, I. H. (2021). New bis ([1,2,4] triazolo) [4,3-a:3',4'-c] quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Bioorganic Chemistry, 112, 104949. https://doi.org/10.1016/j.bioorg.2021.104949
   PubMed Web of Science ®Google Scholar
• Awazu, Y., Nakamura, K., Mizutani, A., Kakoi, Y., Iwata, H., Yamasaki, S., Miyamoto, N., Imamura, S., Miki, H., & Hori, A. (2013). A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Molecular Cancer Therapeutics, 12(6), 913–924. https://doi.org/10.1158/1535-7163.MCT-12-1011
   PubMed Web of Science ®Google Scholar
• Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257–W263. https://doi.org/10.1093/nar/gky318
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology, 4(12), 915–925. https://doi.org/10.1038/nrm1261
   PubMed Web of Science ®Google Scholar
• Cai, Z. W., Wei, D., Schroeder, G. M., Cornelius, L. A., Kim, K., Chen, X. T., Schmidt, R. J., Williams, D. K., Tokarski, J. S., An, Y., Sack, J. S., Manne, V., Kamath, A., Zhang, Y., Marathe, P., Hunt, J. T., Lombardo, L. J., Fargnoli, J., & Borzilleri, R. M. (2008). Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18(11), 3224–3229. https://doi.org/10.1016/j.bmcl.2008.04.047
   PubMed Web of Science ®Google Scholar
• Cee, V. J., Cheng, A. C., Romero, K., Bellon, S., Mohr, C., Whittington, D. A., Bak, A., Bready, J., Caenepeel, S., Coxon, A., Deak, H. L., Fretland, J., Gu, Y., Hodous, B. L., Huang, X., Kim, J. L., Lin, J., Long, A. M., Nguyen, H., … Geuns-Meyer, S. (2009). Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorganic & Medicinal Chemistry Letters, 19(2), 424–427. https://doi.org/10.1016/j.bmcl.2008.11.056
   PubMed Web of Science ®Google Scholar
• Chadha, N., & Silakari, O. (2016). Active site fingerprinting and pharmacophore screening strategies for the identification of dual inhibitors of protein kinase C (ΡΚCβ) and poly (ADP-ribose) polymerase-1 (PARP-1). Molecular Diversity, 20(3), 747–761. https://doi.org/10.1007/s11030-016-9676-9
   PubMed Web of Science ®Google Scholar
• Claridge, S., Raeppel, F., Granger, M.-C., Bernstein, N., Saavedra, O., Zhan, L., Llewellyn, D., Wahhab, A., Deziel, R., Rahil, J., Beaulieu, N., Nguyen, H., Dupont, I., Barsalou, A., Beaulieu, C., Chute, I., Gravel, S., Robert, M.-F., Lefebvre, S., … Vaisburg, A. (2008). Discovery of a novel and potent series of thieno[3,2-b] pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorganic & Medicinal Chemistry Letters, 18(9), 2793–2798. https://doi.org/10.1016/j.bmcl.2008.04.009
   PubMed Web of Science ®Google Scholar
• Comoglio, P. M., Giordano, S., & Trusolino, L. (2008). Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nature Reviews. Drug Discovery, 7(6), 504–516. https://doi.org/10.1038/nrd2530
   PubMed Web of Science ®Google Scholar
• Dain Md Opo, F. A., Alsaiari, A. A., Rahman Molla, M. H., Ahmed Sumon, M. A., Yaghmour, K. A., Ahammad, F., Mohammad, F., & Simal-Gandara, J. (2022). Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process. Frontiers in Chemistry, 10, 986376. https://doi.org/10.3389/fchem.2022.986376
   PubMed Web of Science ®Google Scholar
• D’Angelo, N. D., Bellon, S. F., Booker, S. K., Cheng, Y., Coxon, A., Dominguez, C., Fellows, I., Hoffman, D., Hungate, R., Kaplan-Lefko, P., Lee, M. R., Li, C., Liu, L., Rainbeau, E., Reider, P. J., Rex, K., Siegmund, A., Sun, Y., Tasker, A. S., … Kim, T.-S. (2008). Design, synthesis, and biological evaluation of potent c-Met inhibitors. Journal of Medicinal Chemistry, 51(18), 5766–5779. https://doi.org/10.1021/jm8006189
   PubMed Web of Science ®Google Scholar
• Fu, Y., Liu, Y.-X., Kang, T., Sun, Y.-N., Li, J.-Z., & Ye, F. (2019). Identification of novel inhibitors of p-hydroxyphenylpyruvate dioxygenase using receptor-based virtual screening. Journal of the Taiwan Institute of Chemical Engineers, 103, 33–43. https://doi.org/10.1016/j.jtice.2019.08.005
   Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Gharaghani, S., Khayamian, T., & Ebrahimi, M. (2013). Molecular dynamics simulation study and molecular docking descriptors in structure-based QSAR on acetylcholinesterase (AChE) inhibitors. SAR and QSAR in Environmental Research, 24(9), 773–794. https://doi.org/10.1080/1062936X.2013.792877
   PubMed Web of Science ®Google Scholar
• Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4(1), 17. https://doi.org/10.1186/1758-2946-4-17
   PubMed Web of Science ®Google Scholar
• Hasan, J., Byers, R., & Jayson, G. C. (2002). Intra-tumoural microvessel density in human solid tumours. British Journal of Cancer, 86(10), 1566–1577. https://doi.org/10.1038/sj.bjc.6600315
   PubMed Web of Science ®Google Scholar
• Hassan, A., Badr, M., Abdelhamid, D., Hassan, H. A., Abourehab, M., & Abuo-Rahma, G. (2022). Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold. Bioorganic Chemistry, 120, 105631. https://doi.org/10.1016/j.bioorg.2022.105631
   PubMed Web of Science ®Google Scholar
• Heyman, H. R., Frey, R. R., Bousquet, P. F., Cunha, G. A., Moskey, M. D., Ahmed, A. A., Soni, N. B., Marcotte, P. A., Pease, L. J., Glaser, K. B., Yates, M., Bouska, J. J., Albert, D. H., Black-Schaefer, C. L., Dandliker, P. J., Stewart, K. D., Rafferty, P., Davidsen, S. K., Michaelides, M. R., & Curtin, M. L. (2007). Thienopyridine urea inhibitors of KDR kinase. Bioorganic & Medicinal Chemistry Letters, 17(5), 1246–1249. https://doi.org/10.1016/j.bmcl.2006.12.015
   PubMed Web of Science ®Google Scholar
• Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007). Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling, 19(10), 2003–2012. https://doi.org/10.1016/j.cellsig.2007.05.013
   PubMed Web of Science ®Google Scholar
• Huang, J., Rauscher, S., Nawrocki, G., Ran, T., Feig, M., de Groot, B. L., Grubmüller, H., & MacKerell, A. D., Jr. (2017). CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nature Methods, 14(1), 71–73. https://doi.org/10.1038/nmeth.4067
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–28. https://doi.org/10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• Kim, K. S., Zhang, L., Schmidt, R., Cai, Z.-W., Wei, D., Williams, D. K., Lombardo, L. J., Trainor, G. L., Xie, D., Zhang, Y., An, Y., Sack, J. S., Tokarski, J. S., Darienzo, C., Kamath, A., Marathe, P., Zhang, Y., Lippy, J., Jeyaseelan, R., … Borzilleri, R. M. (2008). Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: Synthesis, X-ray crystallographic analysis, and biological activities. Journal of Medicinal Chemistry, 51(17), 5330–5341. https://doi.org/10.1021/jm800476q
   PubMed Web of Science ®Google Scholar
• Kumar, A., Rajendran, V., Sethumadhavan, R., & Purohit, R. (2013). Molecular dynamic simulation reveals damaging impact of RAC1 F28L mutation in the switch I region. PLoS One, 8(10), e77453. https://doi.org/10.1371/journal.pone.0077453
   PubMed Web of Science ®Google Scholar
• Lai, S., Chen, J. N., Huang, H. W., Zhang, X. Y., Jiang, H. L., Li, W., Wang, P. L., Wang, J., & Liu, F. N. (2018). Structure activity relationships of chrysoeriol and analogs as dual c-Met and VEGFR2 tyrosine kinase inhibitors. Oncology Reports, 40(3), 1650–1656. https://doi.org/10.3892/or.2018.6542
   PubMed Web of Science ®Google Scholar
• Li, J., Gu, W., Bi, X., Li, H., Liao, C., Liu, C., Huang, W., & Qian, H. (2017). Design, synthesis, and biological evaluation of thieno[2,3-d] pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry, 25(24), 6674–6679. https://doi.org/10.1016/j.bmc.2017.11.010
   PubMed Web of Science ®Google Scholar
• Liang, J.-W.,Li, S.-L.,Wang, S.,Li, W.-Q., &Meng, F.-H. (2020). Synthesis and biological evaluation of novel (E)-N'-benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 468–477. https://doi.org/10.1080/14756366.2019.170265531902266
   PubMed Web of Science ®Google Scholar
• Lima, L. R., Bastos, R. S., Ferreira, E. F. B., Leão, R. P., Araújo, P. H. F., Pita, S. S. D. R., De Freitas, H. F., Espejo-Román, J. M., Dos Santos, E. L. V. S., Ramos, R. D. S., Macêdo, W. J. C., & Santos, C. B. R. (2022). Identification of potential new Aedes aegypti juvenile hormone inhibitors from N-Acyl piperidine derivatives: A bioinformatics approach. International Journal of Molecular Sciences, 23(17), 9927. https://doi.org/10.3390/ijms23179927
   PubMed Web of Science ®Google Scholar
• Liu, X., Yao, W., Newton, R. C., & Scherle, P. A. (2008). Targeting the c-MET signaling pathway for cancer therapy. Expert Opinion on Investigational Drugs, 17(7), 997–1011. https://doi.org/10.1517/13543784.17.7.997
   PubMed Web of Science ®Google Scholar
• McTigue, M., Murray, B. W., Chen, J. H., Deng, Y. L., Solowiej, J., & Kania, R. S. (2012). Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 109(45), 18281–18289. https://doi.org/10.1073/pnas.1207759109
   PubMed Web of Science ®Google Scholar
• Miyamoto, N., Sakai, N., Hirayama, T., Miwa, K., Oguro, Y., Oki, H., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Yamasaki, S., Takeuchi, T., Miki, H., Hori, A., & Imamura, S. (2013). Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino] imidazo[1,2-b] pyridazin-6-yl} oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorganic & Medicinal Chemistry, 21(8), 2333–2345. https://doi.org/10.1016/j.bmc.2013.01.074
   PubMed Web of Science ®Google Scholar
• Modi, S. J., & Kulkarni, V. M. (2019). Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: Medicinal chemistry perspective. Medicine in Drug Discovery, 2, 100009. https://doi.org/10.1016/j.medidd.2019.100009
   Google Scholar
• Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking. Journal of Medicinal Chemistry, 55(14), 6582–6594. https://doi.org/10.1021/jm300687e
   PubMed Web of Science ®Google Scholar
• Nada, H., Lee, K., Gotina, L., Pae, A. N., & Elkamhawy, A. (2022). Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches. Computers in Biology and Medicine, 142, 105217. https://doi.org/10.1016/j.compbiomed.2022.105217
   PubMed Web of Science ®Google Scholar
• Neben, C. L., Lo, M., Jura, N., & Klein, O. D. (2019). Feedback regulation of RTK signaling in development. Developmental Biology, 447(1), 71–89. https://doi.org/10.1016/j.ydbio.2017.10.017
   PubMed Web of Science ®Google Scholar
• Oguro, Y., Miyamoto, N., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010). Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d] pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorganic & Medicinal Chemistry, 18(20), 7260–7273. https://doi.org/10.1016/j.bmc.2010.08.017
   PubMed Web of Science ®Google Scholar
• Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2014). Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Medicinal Chemistry Letters, 6(1), 89–94. https://doi.org/10.1021/ml500394m
   PubMed Web of Science ®Google Scholar
• Parikh, P. K., & Ghate, M. D. (2018). Recent advances in the discovery of small molecule c-Met Kinase inhibitors. European Journal of Medicinal Chemistry, 143, 1103–1138. https://doi.org/10.1016/j.ejmech.2017.08.044
   PubMed Web of Science ®Google Scholar
• Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
   PubMed Web of Science ®Google Scholar
• Pradeepkiran, J. A., Kumar, K. K., Kumar, Y. N., & Bhaskar, M. (2015). Modeling, molecular dynamics, and docking assessment of transcription factor rho: A potential drug target in Brucella melitensis 16M. Drug Design, Development and Therapy, 9, 1897–1912. https://doi.org/10.2147/DDDT.S77020
   PubMed Web of Science ®Google Scholar
• Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K. A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., Lougheed, J., Yakes, F. M., Bentzien, F., Xu, W., Zaks, T., Wooster, R., Greshock, J., & Joly, A. H. (2009). Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Research, 69(20), 8009–8016. https://doi.org/10.1158/0008-5472.CAN-08-4889
   PubMed Web of Science ®Google Scholar
• Salmaso, V., & Moro, S. (2018). Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Frontiers in Pharmacology, 9, 923. https://doi.org/10.3389/fphar.2018.00923
   PubMed Web of Science ®Google Scholar
• Selvam, C., Mock, C. D., Mathew, O. P., Ranganna, K., & Thilagavathi, R. (2020). Discovery of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors by ligand-based virtual high throughput screening. Molecular Informatics, 39(7), e1900150. https://doi.org/10.1002/minf.201900150
   PubMed Web of Science ®Google Scholar
• Shi, L., Wu, T. T., Wang, Z., Xue, J. Y., & Xu, Y. G. (2014). Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2. Bioorganic & Medicinal Chemistry, 22(17), 4735–4744. https://doi.org/10.1016/j.bmc.2014.07.008
   PubMed Web of Science ®Google Scholar
• Shi, W., Qiang, H., Huang, D., Bi, X., Huang, W., & Qian, H. (2018). Exploration of novel pyrrolo[2,1-f] [1,2,4] triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2. European Journal of Medicinal Chemistry, 158, 814–831. https://doi.org/10.1016/j.ejmech.2018.09.050
   PubMed Web of Science ®Google Scholar
• Susanti, N., Damayanti, S., Kartasasmita, R. E., & Tjahjono, D. H. (2021). A search for cyclin-dependent kinase 4/6 inhibitors by pharmacophore-based virtual screening, molecular docking, and molecular dynamic simulations. International Journal of Molecular Sciences, 22(24), 13423. https://doi.org/10.3390/ijms222413423
   PubMed Web of Science ®Google Scholar
• Temml, V., Garscha, U., Romp, E., Schubert, G., Gerstmeier, J., Kutil, Z., Matuszczak, B., Waltenberger, B., Stuppner, H., Werz, O., & Schuster, D. (2017). Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening. Scientific Reports, 7, 42751. https://doi.org/10.1038/srep42751
   PubMed Web of Science ®Google Scholar
• Tímár, J., &Döme, B. (2008). Antiangiogenic drugs and tyrosine kinases. Anti-Cancer Agents in Medicinal Chemistry, 8(5), 462–469. https://doi.org/10.2174/18715200878453303518537529
   PubMed Web of Science ®Google Scholar
• Toi, M., Matsumoto, T., & Bando, H. (2001). Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. The Lancet. Oncology, 2(11), 667–673. https://doi.org/10.1016/S1470-2045(01)00556-3
   PubMed Web of Science ®Google Scholar
• Tran, Q.-H., Nguyen, Q.-T., Vo, N.-Q.-H., Mai, T. T., Tran, T.-T.-N., Tran, T.-D., Le, M.-T., Trinh, D.-T T., & Thai, K.-M. (2022). Structure-based 3D-Pharmacophore modeling to discover novel interleukin 6 inhibitors: An in silico screening, molecular dynamics simulations and binding free energy calculations. PLoS One, 17(4), e0266632. https://doi.org/10.1371/journal.pone.0266632
   PubMed Web of Science ®Google Scholar
• Tripathy, R., Ghose, A., Singh, J., Bacon, E. R., Angeles, T. S., Yang, S. X., Albom, M. S., Aimone, L. D., Herman, J. L., & Mallamo, J. P. (2007). 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 17(6), 1793–1798. https://doi.org/10.1016/j.bmcl.2006.12.054
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & Mackerell, A. D., Jr. (2010). CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690. https://doi.org/10.1002/jcc.21367
   PubMed Web of Science ®Google Scholar
• Wang, S., Jiang, J. H., Li, R. Y., & Deng, P. (2020). Docking-based virtual screening of TβR1 inhibitors: Evaluation of pose prediction and scoring functions. BMC Chemistry, 14(1), 52. https://doi.org/10.1186/s13065-020-00704-3
   PubMed Web of Science ®Google Scholar
• Xie, J., Meng, D., Li, Y., Li, R., & Deng, P. (2022). Virtual screening for potential discoidin domain receptor 1 (DDR1) inhibitors based on structural assessment. Molecular Diversity. https://doi.org/10.1007/s11030-022-10557-8
   Web of Science ®Google Scholar
• Xu, H., Wang, M., Wu, F., Zhuo, L., Huang, W., & She, N. (2020). Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorganic & Medicinal Chemistry, 28(12), 115555. https://doi.org/10.1016/j.bmc.2020.115555
   PubMed Web of Science ®Google Scholar
• Zhang, J., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., & Ouyang, L. (2016). Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry, 108, 495–504. https://doi.org/10.1016/j.ejmech.2015.12.016
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Zhang, T. J., Tu, S., Zhang, Z. H., & Meng, F. H. (2020). Identification of novel Src inhibitors: Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulations. Molecules, 25(18), 4094. https://doi.org/10.3390/molecules25184094
   PubMed Web of Science ®Google Scholar
• Zillhardt, M., Park, S. M., Romero, I. L., Sawada, K., Montag, A., Krausz, T., Yamada, S. D., Peter, M. E., & Lengyel, E. (2011). Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clinical Cancer Research, 17(12), 4042–4051. https://doi.org/10.1158/1078-0432.CCR-10-3387
   PubMed Web of Science ®Google Scholar